title: Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center.
authors.forename: Thierry
authors.initials: T
authors.lastname: Ducruet
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Levasseur
authors.forename: Anne
authors.initials: A
authors.lastname: Des Roches
authors.forename: Ayman
authors.initials: A
authors.lastname: Kafal
authors.forename: Renée
authors.initials: R
authors.lastname: Dicaire
authors.forename: Elie
authors.initials: E
authors.lastname: Haddad
mesh_terms: D002170:Canada; D002648:Child; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000191:economics*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D012189:Retrospective Studies
chemical_list: D016756:Immunoglobulins, Intravenous